NR1D1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
== Radiolabeled somatostatin receptor antagonists in Peptide Radionuclide Receptor Therapy (PRRT) == Somatostatin receptor antagonists are also being developed as therapeutic agents in peptide radionuclide receptor therapy (PRRT) due to the wider binding of antagonists compared to agonists. Research indicated the antagonist Lu-DOTA-JR11 showed a higher tumor uptake, more double-strand breaks within tumor cells, longer adherence time to tumors and improved tumor-to-kidney dose ratio. Moreover, another study finds out the radionuclide terbium-161, which can release short-ranged electrons, can combine with somatostatin receptor antagonists that localize at the cell membrane. acting as an alternative to the current clinically used lutetium-somatostatin receptor agonist, which are localized at the cytoplasm and nucleus. Moreover, Tb-antagonist in vitro shows 102-fold higher potency than Lu-antagonists in inhibiting tumor cell growth and survival prolongation in mice, due to its high linear energy transfer. This result is further repeated and confirmed in vivo, showing the high potential and strengths of radiolabeled somatostatin receptor antagonists to treat neuroendocrine neoplasms.
In 1958, Korolev upgraded the R-7 to be able to launch a 400-kilogram (880 lb) payload to the Moon. The Luna program began with three failed secret 1958 attempts to launch Luna E-1-class impactor probes. The fourth attempt, Luna 1, launched successfully on January 2, 1959, but missed the Moon. The fifth attempt on June 18 also failed at launch. The 390-kilogram (860 lb) Luna 2 successfully impacted the Moon on September 14, 1959. The 278.5-kilogram (614 lb) Luna 3 successfully flew by the Moon and sent back pictures of its far side on October 7, 1959. The US first embarked on the Pioneer program in 1958 by launching the first probe, albeit ending in failure. A subsequent probe named Pioneer 1 was launched with the intention of orbiting the Moon only to result in a partial mission success when it reached an apogee of 113,800 km before falling back to Earth. The missions of Pioneer 2 and Pioneer 3 failed whereas Pioneer 4 had one partially successful lunar flyby in March 1959.
The hormonal IUD is inserted in a similar procedure to the nonhormonal copper IUD, and can only be inserted by a qualified medical practitioner. Before insertion, a pelvic exam is performed to examine the shape and position of the uterus. A current STI at the time of insertion can increase the risk of pelvic infection. However, routine screening for gonorrhea and chlamydia prior to insertion is not recommended. If a person needs screening and there is no evidence of infection on examination or has been previously screened, insertion of the IUD does not need to be delayed.
==== Degranulation ==== Neutrophils also release an assortment of proteins in three types of granules by a process called degranulation. The contents of these granules have antimicrobial properties, and help combat infection. Glitter cells are polymorphonuclear leukocyte neutrophils with granules. Degranulation is postulated to occur in a hierarchical manner, with the sequential release of secretory vesicles, tertiary granules, specific granules, and azurophilic granules in response to increasing intracellular calcium concentrations. The release of neutrophils by degranulation occurs through exocytosis, regulated by exocytotic machinery including SNARE proteins, RAC2, RAB27, and others.
== Reactivity ratios == The reactivity ratio of a growing copolymer chain terminating in a given monomer is the ratio of the reaction rate constant for addition of the same monomer and the rate constant for addition of the other monomer. That is,
Sources: en.wikipedia.org
During the 1971–72 season, she co-starred as barmaid Ruth in Nichols, a James Garner–led Western, which aired 22 episodes on NBC. During an August 3, 1970, interview on The Dick Cavett Show, Kidder stated that she was ambivalent toward having a film career, and was considering working as a film editor in the future. At this time, she had become an acquaintance of director Robert Altman, and served as an apprentice assisting him in editing Brewster McCloud (1970). She subsequently appeared in "Such Dust As Dreams Are Made On", the first pilot for Harry O, which aired in March 1973. She was a guest star in a 1972 episode of the George Peppard detective series Banacek. After moving to Los Angeles, Kidder was cast opposite Gene Wilder in Quackser Fortune Has a Cousin in the Bronx (1970) as an exchange student in Ireland who becomes the love interest of a poor horse manure collector in Dublin, whom she almost runs over with her car. After filming in Ireland, Kidder relocated to New York City to study acting further. A year later, she returned to California, and was cast in the Brian De Palma film Sisters (1972), which gained notoriety for both the director and Kidder, who as leading lady, portrayed conjoined twins, one of whom is a suspect in a brutal murder. Kidder had been in a relationship with De Palma at the time, and had been roommates with co-star Jennifer Salt in Los Angeles.
Chloral hydrate is a geminal diol with the formula Cl3C−CH(OH)2. It was first used as a sedative and hypnotic in Germany in the 1870s. Over time it was replaced by safer and more effective alternatives but it remained in use in the United States until at least the 1970s. It sometimes finds usage as a laboratory chemical reagent and precursor. It is derived from chloral (trichloroacetaldehyde) by the addition of one equivalent of water.
Chemistry... Key to Better Living. Diamond Jubilee Volume: A Record of Chemical Progress During the First 75 Years of the American Chemical Society. American Chemical Society. 1951. Skolnik, Herman; Reese, Kenneth M., eds. (1976). A Century of chemistry: the role of chemists and the American Chemical Society. Washington, D.C.: American Chemical Society. ISBN 978-0841203075. J. J. Bohning 2001. American Chemical Society Founded 1876. ACS, Washington, D.C. Reese, Kenneth M., ed. (2002). The American Chemical Society at 125: A recent history 1976–2001. American Chemical Society. ISBN 978-0-8412-3851-0. ACS website ACS Publications website ACS Chemical & Engineering News ACS Chemical Abstracts Service (CAS) International Year of Chemistry 2011(archived) A Cauldron Bubbles: PubChem and the American Chemical Society — Information Today, June 2005 ACS Chemical Biology WIKI(archived) ACS Chemical Biology Community(archived) ACS Green Chemistry Institute ACS Organic Division Leete Award Gassman Award
Thus tetravalent protactinium in solutions is obtained by the action of strong reducing agents in a hydrogen atmosphere. Tetravalent protactinium is chemically similar to uranium(IV) and thorium(IV). Fluorides, phosphates, hypophosphates, iodates and phenylarsonates of protactinium(IV) are insoluble in water and dilute acids. Protactinium forms soluble carbonates. The hydrolytic properties of pentavalent protactinium are close to those of tantalum(V) and niobium(V). The complex chemical behavior of protactinium is a consequence of the start of the filling of the 5f shell in this element. Uranium has a valence from 3 to 6, the last being most stable. In the hexavalent state, uranium is very similar to the group 6 elements. Many compounds of uranium(IV) and uranium(VI) are non-stoichiometric, i.e. have variable composition. For example, the actual chemical formula of uranium dioxide is UO2+x, where x varies between −0.4 and 0.32. Uranium(VI) compounds are weak oxidants. Most of them contain the linear "uranyl" group, UO2+2. Between 4 and 6 ligands can be accommodated in an equatorial plane perpendicular to the uranyl group. The uranyl group acts as a hard acid and forms stronger complexes with oxygen-donor ligands than with nitrogen-donor ligands. NpO2+2 and PuO2+2 are also the common form of Np and Pu in the +6 oxidation state. Uranium(IV) compounds exhibit reducing properties, e.g., they are easily oxidized by atmospheric oxygen. Uranium(III) is a very strong reducing agent.
Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2. It was patented in 1983 and approved for medical use in 1997. It was subsequently withdrawn.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.